UEG Week 2022

What is new in anti-TNFα therapy?

Treat-to-target with ustekinumab - why didn't it work?

The benefit of early intervention in CD

What is the best dose of adalimumab in CD?

Is IL-23 the super target?

Personalized therapy - de-escalation strategies

Treat-to-target still alive?

Explosion of new drugs

T reg - a new therapeutic target in IBD?

Anti-IL-23 monoclonal antibodies: is it better to target IL-23 only than IL-23 and IL-12?

Thinking out of the box - co-medication of the elderly

Once more a shocking message: be aware of steroids!

Pharmacokinetics of ustekinumab in the STARDUST trial

You can still treat severe biofailure in CD

Oral anti-integrin therapy in IBD - new data, new chances?

Postoperative monitoring matters!

Treating the patient as a whole

Small molecules in crohn's disease

VEGA - the story continues

Enhanced treatment algorithm for the management of CD

Treat-to-target strategy is superior to conventional step-care in active patients to gain remission

Longterm potential benefit of a combIo therapy

No matter what you use - treat early!

TYK2 Deucravacitinib in ulcerative colitis

Combination therapy: week 38 efficacy and safety data from the VEGA study

Thinking out of the box - Einfluss der Begleitmedikation bei älteren Patienten

Explosión de nuevos fármacos

Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα κορτικοστεροιδή!

Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!

Terapia di combinazione: efficacia e sicurezza a 38 settimane nello studio VEGA

Les résultats à long terme d'une combIothérapie

Una strategia “Treat-to-target” è superiore rispetto and un approccio convenzionale nel raggiungimento della remissione in pazienti con malattia attiva

Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά νόσο του Crohn

Doustna terapia antyintegrynowa - nowe dane, nowe nadzieje?

T reg - nowy cel terapeutyczny w IBD?

TYK2 Deucravacitinib bei Colitis ulcerosa

Treating the patient as a whole

Anticorps anti-IL-23: est-il préferabble de cibler l'IL-23 seule plutôt que l'IL-12 et l'IL-23?

VEGA - l'histoire continue

Was tun nach der Operation?

Small molecules nel morbo di crohn

Update on IL-23 inhibition in UC

1st JAK inhibitor in CD - a game changer?

Update on JAK inhibition in UC

S1P receptor modulators

Persistance on therapy and real-world clinical effectiveness of Tofacitinib in ulcerative colitis: data from the ENEIDA registry

Upadacitinib - induction therapy in CD

Risankizumab in refractory CD patients

Estrasimod in moderate to severe active UC

Selective IL-23 blockade

Histological response and remission induced by mirikizumab

Upadacitinib maintenance therapy - final results from U-ACHIEVE

Final efficacy and safety results from Upadacitinib 52 weeks maintenance trial in UC patients

The era of small molecules

VEGA & LUCENT studies

Ozanimod works in young and old UC patient

The 1st JAKi in CD

JAK-inhibition

VEGA & LUCENT studi clinici

Selective IL-23 Blockade

Persistenza in terapia ed efficaci clinica di Tofacitinib in colite ulcerosa: dati dal registro ENEIDA

Risankizumab dans la maladie de Crohn réfractaire

Upadacitinib - Induktionsdaten bei CD

The area of small molecules

Risultati finali di efficacia e sicurezza a 52 settimane di Upadacitinib in colite ulcerosa

JAK-Inhibition

Treating the elderly - closer surveillance and the importance of co-medication

Updated safety data on JAK inhibitors

Steroid effects as treatment goals: quality of life and steroid free remission

Urgency - putting the focus on an important endpoint!

New endpoints in IBD

Filgotinib is efficacious in inducing and maintaining histological remission in UC

Patient reported outcomes in IBD

Urgency matters!

Patienten gerichtete Endpunkte bei CED

Neue Studienendpunkte in IBD

Whats's the origin of Crohn's genetics ? The history of IL-23 receptor genetics in Europe

Explosion of Spanish contributions

Explosión de las comunicaciones españolas

Wo kommt die Crohn-Genetik her? Die Historie der IL-23 Rezeptorgenetik in Europa

Personalised therapy in IBD

Individualisierte Therapie bei CED